BIOMAT Database Logo BIOMAT Database Logo

Amelioration of negative symptoms in schizophrenia by glycine. 1994

D C Javitt, and I Zylberman, and S R Zukin, and U Heresco-Levy, and J P Lindenmayer
Department of Psychiatry, Albert Einstein College of Medicine, Bronx Psychiatric Center, NY 10461.

Phencyclidine induces a psychotomimetic state by blocking neurotransmission at N-methyl-D-aspartic acid (NMDA) receptors. In a double-blind, placebo-controlled fashion, 14 medicated patients with chronic schizophrenia were treated with glycine, a potentiator of NMDA-receptor-mediated neurotransmission. Significant improvement in negative symptoms occurred in the group given glycine but not in the group given placebo, suggesting that potentiation of NMDA-receptor-mediated neurotransmission may represent an effective treatment for neuroleptic-resistant negative symptoms in schizophrenia.

UI MeSH Term Description Entries
D008297 Male Males
D009435 Synaptic Transmission The communication from a NEURON to a target (neuron, muscle, or secretory cell) across a SYNAPSE. In chemical synaptic transmission, the presynaptic neuron releases a NEUROTRANSMITTER that diffuses across the synaptic cleft and binds to specific synaptic receptors, activating them. The activated receptors modulate specific ion channels and/or second-messenger systems in the postsynaptic cell. In electrical synaptic transmission, electrical signals are communicated as an ionic current flow across ELECTRICAL SYNAPSES. Neural Transmission,Neurotransmission,Transmission, Neural,Transmission, Synaptic
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005998 Glycine A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. Aminoacetic Acid,Glycine, Monopotassium Salt,Glycine Carbonate (1:1), Monosodium Salt,Glycine Carbonate (2:1), Monolithium Salt,Glycine Carbonate (2:1), Monopotassium Salt,Glycine Carbonate (2:1), Monosodium Salt,Glycine Hydrochloride,Glycine Hydrochloride (2:1),Glycine Phosphate,Glycine Phosphate (1:1),Glycine Sulfate (3:1),Glycine, Calcium Salt,Glycine, Calcium Salt (2:1),Glycine, Cobalt Salt,Glycine, Copper Salt,Glycine, Monoammonium Salt,Glycine, Monosodium Salt,Glycine, Sodium Hydrogen Carbonate,Acid, Aminoacetic,Calcium Salt Glycine,Cobalt Salt Glycine,Copper Salt Glycine,Hydrochloride, Glycine,Monoammonium Salt Glycine,Monopotassium Salt Glycine,Monosodium Salt Glycine,Phosphate, Glycine,Salt Glycine, Monoammonium,Salt Glycine, Monopotassium,Salt Glycine, Monosodium
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D012565 Schizophrenic Psychology Study of mental processes and behavior of schizophrenics. Psychology, Schizophrenic
D016194 Receptors, N-Methyl-D-Aspartate A class of ionotropic glutamate receptors characterized by affinity for N-methyl-D-aspartate. NMDA receptors have an allosteric binding site for glycine which must be occupied for the channel to open efficiently and a site within the channel itself to which magnesium ions bind in a voltage-dependent manner. The positive voltage dependence of channel conductance and the high permeability of the conducting channel to calcium ions (as well as to monovalent cations) are important in excitotoxicity and neuronal plasticity. N-Methyl-D-Aspartate Receptor,N-Methyl-D-Aspartate Receptors,NMDA Receptor,NMDA Receptor-Ionophore Complex,NMDA Receptors,Receptors, NMDA,N-Methylaspartate Receptors,Receptors, N-Methylaspartate,N Methyl D Aspartate Receptor,N Methyl D Aspartate Receptors,N Methylaspartate Receptors,NMDA Receptor Ionophore Complex,Receptor, N-Methyl-D-Aspartate,Receptor, NMDA,Receptors, N Methyl D Aspartate,Receptors, N Methylaspartate

Related Publications

D C Javitt, and I Zylberman, and S R Zukin, and U Heresco-Levy, and J P Lindenmayer
Glycine serum level in schizophrenia: relation to negative symptoms.
April 2010, Psychiatry research,
D C Javitt, and I Zylberman, and S R Zukin, and U Heresco-Levy, and J P Lindenmayer
Glycine and D-serine improve the negative symptoms of schizophrenia.
August 2005, Evidence-based mental health,
D C Javitt, and I Zylberman, and S R Zukin, and U Heresco-Levy, and J P Lindenmayer
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
January 1999, Archives of general psychiatry,
D C Javitt, and I Zylberman, and S R Zukin, and U Heresco-Levy, and J P Lindenmayer
[Negative symptoms in schizophrenia].
June 1993, Harefuah,
D C Javitt, and I Zylberman, and S R Zukin, and U Heresco-Levy, and J P Lindenmayer
Negative symptoms in schizophrenia.
August 1990, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
D C Javitt, and I Zylberman, and S R Zukin, and U Heresco-Levy, and J P Lindenmayer
Negative symptoms in schizophrenia.
January 2016, Industrial psychiatry journal,
D C Javitt, and I Zylberman, and S R Zukin, and U Heresco-Levy, and J P Lindenmayer
Negative symptoms in schizophrenia.
April 2014, Clinical schizophrenia & related psychoses,
D C Javitt, and I Zylberman, and S R Zukin, and U Heresco-Levy, and J P Lindenmayer
Negative symptoms in schizophrenia.
September 1991, The American journal of psychiatry,
D C Javitt, and I Zylberman, and S R Zukin, and U Heresco-Levy, and J P Lindenmayer
Negative symptoms and negative schizophrenia.
July 1984, Indian journal of psychiatry,
D C Javitt, and I Zylberman, and S R Zukin, and U Heresco-Levy, and J P Lindenmayer
Negative symptoms of schizophrenia.
March 1992, The Practitioner,
Copied contents to your clipboard!